AHR and atrial fibrillation: This study not only provides insights into the molecular mechanisms of action of AF (a ligand of AhR), given alone and in combination with vorinostat (a HDAC inhibitor), but also opens new possibilities for a molecularly targeted approach to treating aggressive mesenchymal-like TNBC.